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Proteomic patterns established with capillary electrophoresis
and mass spectrometry for diagnostic purposes.
Background. Proteomics applied in large scale may provide
a useful diagnostic tool.
Methods. We developed an online combination of capil-
lary electrophoresis with mass spectrometry, allowing fast and
sensitive evaluation of polypeptides found in body fluids. Uti-
lizing this technology, polypeptide patterns from urine are es-
tablished within 45 minutes. About 900 to 2500 polypeptides
as well as their concentrations are detected in individual urine
samples without the need for specific reagents such as antibod-
ies. To test this method for clinical application, we examined
spot urine samples from 57 healthy individuals, 16 patients with
minimal change disease (MCD), 18 patients with membranous
glomerulonephritis (MGN), and 10 patients with focal segmen-
tal glomerulosclerosis (FSGS).
Results. One-hundred seventy-three polypeptides were
present in more than 90% of the urine samples obtained from
healthy individuals, while 690 polypeptides were present with
more than 50% probability. These data permitted the establish-
ment of a “normal” polypeptide pattern in healthy individuals.
Polypeptides found in the urine of patients differed significantly
from the normal controls. These differences allowed the distinc-
tion of specific protein spectra in patients with different primary
renal diseases. Abnormal pattern of proteins were found even
in urine from patients in clinical remission.
Conclusion. The data indicate that capillary electrophore-
sis with mass spectrometry coupling provides a promising tool
that permits fast and accurate identification and differentiation
of protein patterns in body fluids of healthy and diseased indi-
viduals, thus enabling diagnosis based on these patterns.
Analysis of the proteome is the main task in the post
genomic era. A number of processes in the body may
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be reflected by polypeptides present in body fluids such
as serum or urine [1, 2]. Unfortunately, in terms of dif-
ferential diagnosis, protein assessment has thus far been
neither sensitive nor specific. Western blotting and other
immunologic methods have been employed, but these
techniques identify only a few proteins in one step [2,
3]. Proteomic analysis is now available for a large-scale
study of proteins in tissues and body fluids [4, 5]. Two-
dimensional polyacrylamide gel electrophoresis (PAGE)
is commonly used for protein separation and can be
combined with mass spectrometry yielding identifica-
tion of individual proteins. Over 1000 protein spots can
be discerned with two-dimensional-PAGE [6, 7]. How-
ever, since each single spot must be analyzed separately
by mass spectometry/mass spectometry for identifica-
tion, these techniques are too cumbersome for routine
use. Surface-enhanced laser desorption and ionization
(SELDI) mass spectrometry is another important tool
employed for high throughput analyses of biological sam-
ples [8, 9]. It is based on the specific binding of a frac-
tion of the polypeptides present in a complex sample
to different matrices and the subsequent analysis of the
bound polypeptides with a time-of-flight mass spectrom-
eter. This of course limits the analysis to the few polypep-
tides that actually bind to the chip surface under the
conditions applied. Since these polypeptides represent
only a very small fraction of the polypeptides present
in these complex samples, a broad pattern cannot be
obtained.
If the proteins could all be identified in a single, time-
limited step, proteomics of urine could serve as a powerful
tool for clinical application. A new, alternative technol-
ogy relying on capillary electrophoresis coupled to mass
spectrometry with a software specifically designed to deal
with the enormous amounts of data generated could be a
step in that direction. This technique permits the analysis
of several hundred urinary polypeptides simultaneously
in a short time in a small volume with a high sensitivity.
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Here the feasibility for clinical application was tested by
comparing the urinary polypeptide patterns from healthy
individuals and from patients with primary renal disease.
METHODS
Participants
After local Ethics Committee approval, informed con-
sent was obtained from all participants. We examined a
group of 57 healthy individuals with normal renal func-
tion in order to establish normal urinary protein pat-
terns with capillary electrophoresis-mass spectometry.
In addition, we studied 44 patients with biopsy-proven
minimal change disease (MCD) (N = 16), membranous
glomerulonephritis (MGN) (N = 18), and focal segmen-
tal glomerulosclerosis (FSGS) (N = 10) (Table 1).
Capillary electrophoresis-mass spectrometry analysis
Spot urine samples were collected from all participants
in the morning after voiding the first urine. Samples were
prepared as described in detail elsewhere [10]. The cap-
illary electrophoresis-mass spectrometry analysis was es-
tablished as described previously [11], using a Beckman
Coulter PAC/E system (Fullerton, CA, USA) coupled to
a Mariner TOF mass spectrometer (ABI, Applied Biosys-
tems, Foster City, CA, USA). Electrophoresed capillar-
ies were from Beckman, inner diameter/outer diameter
75/360 lm and 90 cm in length. The mobile phase used
contained 30% methanol and 0.5% formic acid in wa-
ter. The same liquid was used for the sheath flow, which
was applied at 5 lL/min. Sample injection was performed
with pressure 1 psi for 20 seconds. Under these condi-
tions about 200 nL of sample could be injected. The sub-
sequent capillary electrophoresis-mass spectrometry run
was performed at +30 kV with 0.2 psi positive pressure
for 60 minutes. After each run, the electrophoresed cap-
illary was rinsed for 5 minutes with 0.1 mol/L NaOH, fol-
lowed by 5 minutes with water and 5 minutes with running
buffer.
Statistical analysis
For discrimination between healthy subjects and dif-
ferent groups of patients with renal diseases we used
the method of Random Forests and the correspond-
ing S-Plus program, version 6/2002 (http://oz.berkeley.
edu/users/breiman/randomforest2001.pdf). In this pro-
cedure, a series of polypeptide subsets of fixed size is
selected randomly from all candidate polypeptides. For
each subset, a classification tree as described in the Clas-
sification and Regression Tree (CART) analysis is gen-
erated [12], resulting in a classification rule. The forest
prediction is the unweight plurality of class votes of the
series of classification rules. Overfitting is not generated
due to large numbers of subset selections. The estimated
Table 1. Clinical data of patients with focal-segmental
glomerulosclerosis (FSGS), membranous glomerulonephritis (MGN),
and minimal change disease (MCD)
Serum
creatinine Proteinuria Immuno-
Gender Age Diagnosis lmol/L g/day suppression
M 63 FSGS 95 0.02 PS
M 18 FSGS 99 0.05 CsA
M 63 FSGS 93 0.05 PS
F 49 FSGS 80 0.05 CsA + PS
F 23 FSGS 69 0.54 CsA
F 26 FSGS 16 0.7 CsA
F 56 FSGS 80 0.8 —
M 62 FSGS 150 1.9 —
M 26 FSGS 144 4.9 —
F 26 FSGS 150 11.0 CsA + PS
M 69 MGN 128 0.02 CsA
M 62 MGN 91 0.17 —
M 23 MGN 150 0.3 —
M 37 MGN 73 0.33 —
M 43 MGN 82 0.7 PS
M 48 MGN 100 1.0 CsA + PS
F 68 MGN 150 1.0 —
F 21 MGN 80 1.0 CsA + PS
M 44 MGN 118 1.0 CsA
M 45 MGN 93 1.3 —
M 48 MGN 133 2.4 —
M 37 MGN 93 2.6 —
M 78 MGN 99 3.3 —
M 47 MGN 93 3.5 PS
F 34 MGN 80 3.5 CsA + PS
M 66 MGN 132 3.6 —
M 38 MGN 100 4.0 CsA + PS
M 43 MGN 85 5.1 —
F 43 MCD 114 0.01 CsA
M 45 MCDa 93 0.01 —
F 52 MCDa 118 0.01 —
M 52 MCD 93 0.01 —
F 44 MCDa 80 0.02 CsA
M 39 MCDb 93 0.02 —
M 51 MCD 93 0.05 —
M 18 MCD 77 0.05 CsA + PS
F 70 MCDb 95 0.08 —
M 69 MCD 93 0.08 —
F 29 MCDa 160 0.1 —
M 62 MCDa 93 0.1 —
M 21 MCD 57 0.12 —
F 43 MCD 114 0.01 CsA
F 25 MCD 80 1.2 —
M 52 MCD 93 0.4 PS
F 80 MCDa 145 7.9 —
Abbreviations are: M, male; F, female; CsA, cyclosporine A; PS, prednisolone;
—, currently no immmunosupression.
aFrequent relapse; bdifferential diagnosis: FSGS.
generalization error is unbiased due to the method of
“out of bag” (oob) estimation. Each tree is grown on a
bootstrap sample of cases of the learning sample and the
validation is estimated on the basis of those cases not
selected in the bootstrap sample.
Further, discrimination between groups was also per-
formed using support vector machines. This tool has the
advantage of discriminating data in high dimensional pa-
rameter space. Its fast and stable algorithms showed good
performance in the evaluation of clinical markers [13] and
different areas of biologic analyses like DNA arrays [14].
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1012,5 17,2 0,7 762,0
1024,4 16,2 0,3 541,0
1028,3 17,3 0,3 3382,6
1031,4 10,6 0,2 477,9
1040,1 18,1 0,4 735,1
1046,9 31,6 0,5 336,6
1047,4 10,6 0,2 921,9
1050,5 27,7 0,8 2125,5
1059,1 10,3 0,3 685,0
1063,4 16,6 0,1 358,5
1075,3 10,9 0,4 981,2
1083,3 18,4 0,3 1319,7
1096,3 18,9 0,3 790,6
1099,3 18,3 0,2 574,6
1107,3 19,9 0,1 244,6
1110,3 19,2 0,3 510,4
1113,9 17,6 0,7 739,9
CE-t[min] dt[min] amplitude
TIC
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Table 2. List of internal polypeptide standards
Capillary Capillary
electrophoresis electrophoreis
Mass D minutes dt minutes Amplitude Mass D minutes dt minutes Amplitude
879.57562 24.5572 0.2707 1462.7582 2205.2424 40.509525 0.1998 800.39626
882.57745 38.2353 0.3372 4101.7073 2266.0837 25.30299 0.2489 1110.9188
943.53906 30.7149 0.1204 169.38108 2343.1943 47.250206 0.0594 160.92933
962.68243 26.8435 0.3355 2733.2768 2385.6533 46.270077 0.1986 3605.8205
980.55707 36.3253 0.1268 850.21077 2389.6716 35.208801 0.1336 1596.6981
995.84705 38.1813 0.1167 185.42235 2427.3577 21.396704 0.1742 5544.1725
1000.5325 36.4112 0.1198 1264.3272 2584.3467 47.52927 0.2081 1894.3667
1008.5493 36.3938 0.1224 1023.485 2608.7554 58.892986 0.3801 744.93676
1046.5685 39.4718 0.102 1970.8255 2642.4868 40.773842 0.1323 2883.9746
1060.6541 29.9184 0.2624 882.45896 2650.2124 47.164146 0.2098 1495.2113
1099.7209 31.2757 0.1898 239.43964 2663.2527 36.758789 0.1277 2337.8207
1108.6787 30.7498 0.2105 1390.4321 2717.6538 36.734684 0.0994 945.97469
1134.6041 37.6726 0.1395 9450.3494 2742.2117 41.805714 0.1385 13418.287
1160.5643 48.4477 0.2377 2710.6561 2767.2473 33.375267 0.1848 4778.9466
1194.5908 40.5223 0.1222 2324.6742 2825.4565 38.103081 0.1371 8998.4029
1195.5426 51.4226 0.3164 2673.3386 2914.4685 26.646198 0.159 217.25591
1211.9031 51.6276 0.1864 394.91299 3098.3833 42.654072 0.1418 2414.725
1223.51 51.3287 0.2332 2296.7473 3108.7236 43.780117 0.1565 1819.5582
1235.5739 40.4158 0.1564 1677.6236 3121.2883 42.940685 0.1361 1557.9795
1250.5521 28.7866 0.2051 491.69921 3122.812 32.15163 0.1952 770.02884
1250.5753 41.6089 0.2051 2654.0288 3152.571 38.032036 0.1414 4167.5262
1261.4485 48.743 0.2086 1959.7763 3209.8943 35.441532 0.2965 3315.5785
1265.621 40.7229 0.1201 7231.4909 3271.6116 43.076786 0.1586 4999.817
1274.5477 49.5887 0.1611 441.75028 3359.8589 44.18988 0.1719 6258.1389
1302.733 34.0667 0.1495 2158.7819 3385.7944 38.70256 0.1423 11459.73
1351.6504 53.1988 0.2781 1114.4341 3405.4702 39.347652 0.169 12984.248
1352.824 37.8293 0.1003 231.02664 3416.7388 44.232269 0.1929 6819.8546
1367.6476 53.2919 0.3169 4690.6562 3442.2415 43.457088 0.174 30349.854
1368.0363 19.7767 0.0585 127.72452 3473.4871 43.514019 0.1776 14240.418
1368.8584 30.9558 0.1023 204.29996 3495.8416 43.483845 0.1677 12254.177
1425.7068 38.7757 0.1297 1350.7146 3556.7791 37.530521 0.1576 6160.1678
1451.673 42.1841 0.143 25518.145 3686.4741 34.683914 0.2342 5419.3438
1463.6616 42.0803 0.129 1062.1906 3723.1045 34.156864 0.2257 22686.806
1473.6721 42.1302 0.1596 2377.2833 3775.8423 39.223991 0.1375 9637.1885
1487.5641 42.6868 0.082 159.82448 3840.4766 22.777105 0.2362 26664.129
1489.5853 42.1194 0.1225 1748.0771 3842.6077 20.451403 0.1913 8206.3252
1507.6904 54.6114 0.4206 8925.2972 3987.4858 31.315405 0.2917 58531.523
1579.6877 42.7698 0.1444 3358.7792 4098.5308 37.749763 0.1918 16579.449
1594.7413 55.108 0.3373 3999.1967 4153.9829 21.452408 0.2052 14184.981
1622.0157 16.0271 0.1648 1150.1964 4154.4185 40.461906 0.1466 1709.0389
1682.7035 30.5251 0.1358 437.58057 4240.9204 21.810133 0.2263 15944.289
1744.0118 37.5614 0.0873 514.21467 4283.0938 22.285761 0.1871 1434.1281
1770.1071 53.1941 0.1835 99.535322 4353.6777 28.135506 0.3779 76807.856
1829.1254 32.1943 0.2255 21675.552 4748.3579 20.489723 0.2777 81717.197
1834.9274 43.6513 0.1561 1422.0567 5001.1816 38.921215 0.1279 8845.1779
1840.7775 57.4979 0.3161 1480.3287 6171.3804 39.916527 0.1742 32116.497
1863.9515 60.1141 0.2882 10879.321 7556.4419 24.291096 0.2543 10782.118
1867.813 24.8126 0.1821 513.97468 8054.6021 15.473908 0.1018 908.40838
1877.7308 20.3359 0.1567 539.08383 8341.2217 15.700283 0.1005 675.1032
1889.5989 45.6802 0.1054 378.81307 8652.6729 15.831989 0.1114 776.32484
1992.1965 42.9788 0.0669 146.71461 8765.3594 15.800179 0.1379 37122.251
2020.9215 59.9668 0.0634 50.039161 9181.2393 16.159319 0.1124 1426.8831
2039.215 34.5547 0.16 18532.815 9221.3975 19.935049 0.1362 1312.4052
2154.2322 39.4601 0.083 503.53119 10045.264 16.630129 0.1564 12094.411
2172.1443 26.1455 0.2207 3395.7047 10388.597 17.654213 0.1274 910.6
2196.7866 45.5114 0.2185 1980.4108 10517.814 17.971323 0.1767 5274.2379
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Fig. 1. The MosaiquesVisu software allows the depiction of the information from a crude capillary electroporesis-mass spectrometry analysis. A
three-dimensional contour plot of urine from a healthy volunteer is shown, mass per charge on the Y-axis against the retention time in min (X-axis),
signal intensity color coded (A, left side). Next, the signal-to-noise is calculated and the noise removed, thus leaving only actual signals (B). The
software calculates the actual mass based on both isotopic distribution and conjugated masses (C). This results in a table of up to 1500 polypeptides
defined via their mass and retention time. As an example, bottom right shows 17 polypeptides found in the sample.
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Fig. 2. The contour plots of polypeptides (ac-
tual masses) for healthy subjects (NC) and
for patients with focal segmental glomeru-
losclerosis (FSGS), minimal change disease
(MCD), and membranous glomerulonephri-
tis (MGN) are shown. The upper mass limit
is indicated on the top left of each plot. As
evident, the contour plots differ significantly
between the healthy subjects and the renal dis-
ease groups.
RESULTS
Normal urinary polypeptide pattern analyzed with
capillary electrophoresis-mass spectrometry
A graphic depiction (contour plot) of a typical sample
is presented in Figure 1 (raw data). In one individual sam-
ple, between 900 and 2500 polypeptides with molecular
weights from 800 up to 30,000 D were detected. Under
the conditions used for capillary electrophoresis polypep-
tides with higher molecular weights tend to precipitate.
Thus larger proteins in general cannot be detected, al-
though some (e.g., albumin) can be visualized. A list of
112 polypeptides present with high probability that were
chosen as internal standards to assure sample compara-
bility is shown in Table 2. Repeated analyses of identical
samples did not reveal any significant differences under
identical conditions of the capillary electrophoresis-mass
spectrometry run for an individual sample (data not
shown).
The subsequent electronic data manipulation for one
example is summarized in Figure 1. Each run results in
the crude spectrum depicted in the top panel of Figure 1
and is composed of single spectra (Fig. 1) generated
every 3 seconds. The vast amount of data generated
was analyzed utilizing the MosaiquesVisu software. Thus,
capillary electrophoresis-mass spectometry peaks were
identified in the first data analysis run (Fig. 1A). Next,
the charge of each peak was ascertained utilizing both
isotopic distribution and conjugated peaks (Fig. 1B). As
a result, conjugated peaks were summarized in one sin-
gle peak and the real mass was calculated (Fig. 1C). Ini-
tially, the samples were spiked with external standards of
known mass. This allowed subsequent definition of inter-
nal standards of polypeptides present with high probabil-
ity in the urine samples. Thus the capillary electrophoresis
time could be normalized to the internal standards. By
applying this technique on an average urine sample,
roughly 1000 polypeptides can be detected and described/
Weissinger et al: Proteomics and nephritis 2431
Table 3. Comparison of polypeptides in normal subjects and patients
Frequency % Frequency %
Mass CE Mass CE
D min Control FSGS MCD MGN D min Control FSGS MCD MGN
3012.09 39.45 100 60 94 72 1028.57 37.79 98 40 69 22
1539.67 50.20 100 90 100 89 876.41 48.89 98 70 38 67
2249.19 33.82 100 80 100 83 2205.03 36.94 98 70 88 83
3152.55 38.22 100 60 69 39 3402.40 33.83 98 50 94 56
3360.09 44.33 100 60 81 72 2377.60 32.06 98 80 94 83
3001.97 48.35 100 100 100 89 2175.03 44.27 98 80 100 100
2257.19 46.60 100 60 81 67 2385.45 45.47 98 80 81 94
2563.42 32.22 100 90 75 72 2046.99 45.39 98 50 56 50
2158.98 46.70 100 90 88 89 2409.90 32.54 98 100 94 94
3287.97 43.92 100 90 100 89 3433.28 44.46 98 70 56 56
3385.76 36.60 100 100 81 72 1545.75 54.72 98 90 100 89
3271.80 44.05 100 80 94 61 2736.31 32.30 97 100 94 89
2007.69 33.06 100 90 88 89 3723.33 32.48 97 20 50 22
1194.61 39.46 100 70 88 83 1737.76 41.29 97 90 88 89
1265.62 40.37 100 70 94 72 1378.54 45.45 97 60 81 56
1435.69 39.91 100 90 94 89 2854.41 43.80 97 50 75 56
1261.53 49.63 100 80 88 61 2068.54 41.06 97 80 81 61
1438.56 37.63 100 100 100 100 2663.36 36.38 97 80 88 83
1446.50 52.53 100 80 94 67 2085.50 39.21 97 100 94 94
3265.77 42.28 100 80 75 78 2682.49 35.03 97 90 75 89
3121.36 42.46 100 50 75 44 1046.57 38.63 97 20 38 6
1911.14 37.40 100 90 100 94 2994.61 40.63 97 90 88 72
1321.91 41.10 100 70 69 50 2583.98 43.75 97 30 62 28
2695.49 35.27 100 70 88 78 2129.48 35.14 97 60 50 17
1235.59 41.42 100 60 69 50 981.56 37.39 97 50 81 56
2799.94 37.08 100 80 88 83 879.55 26.95 97 60 94 22
2169.75 39.56 100 100 100 94 2394.29 36.32 97 100 100 94
1224.74 33.57 100 50 94 33 3986.98 30.46 97 50 69 44
1451.67 41.11 100 100 100 83 2483.58 38.74 97 90 81 78
3479.32 48.53 100 70 75 17 1523.73 54.29 97 90 100 89
2649.94 45.91 100 90 75 78 1889.76 46.38 97 30 44 39
2687.36 41.87 100 60 75 61 1507.64 54.43 97 90 100 89
3458.52 44.64 100 90 94 72 3209.22 34.27 97 30 81 33
3442.84 42.54 100 80 94 56 3022.82 33.82 97 40 62 61
2048.19 33.07 100 40 81 61 1765.17 35.50 97 90 88 94
2679.46 34.99 100 50 94 67 1367.67 53.27 97 90 94 94
2227.34 38.28 100 70 62 83 2726.38 40.38 97 100 88 100
1239.52 50.23 100 100 100 78 1179.57 52.17 97 80 100 83
3098.80 42.63 100 60 81 56 1651.86 55.15 97 90 100 78
2839.07 35.41 100 80 88 83 3376.24 45.17 97 50 88 67
3417.12 45.12 100 70 81 61 3293.15 54.21 97 50 75 50
3426.20 42.48 100 70 88 72 1579.50 39.43 97 100 94 94
3041.16 45.04 100 80 81 39 3474.27 43.37 95 70 75 67
1508.70 41.26 98 90 94 61 2848.83 36.33 95 70 75 44
1462.67 53.58 98 70 88 50 3319.28 46.22 95 50 62 39
3280.96 36.76 98 20 50 22 1000.52 33.96 95 40 44 28
1877.33 29.62 98 100 100 100 3281.97 49.44 95 60 50 56
2742.25 42.25 98 90 75 89 1885.74 57.47 95 70 75 28
3092.71 43.86 98 90 81 78 3556.92 34.85 95 100 75 78
2196.66 45.45 98 80 100 89 1609.17 42.60 95 100 94 89
6187.55 39.78 98 60 94 67 2767.41 31.39 95 40 69 56
2825.42 36.54 98 50 88 39 3108.81 44.70 95 50 75 56
1255.55 49.81 98 100 100 78 2233.00 31.06 95 30 69 56
2717.56 34.43 98 60 69 61 882.55 36.55 95 60 31 72
3149.67 41.62 98 70 88 50 1680.16 37.32 95 100 94 100
1195.53 51.76 98 70 94 83 1673.80 54.59 95 80 94 61
3496.02 43.85 98 90 94 61 2336.78 42.47 95 70 94 89
1561.69 54.17 98 90 100 83 1217.64 48.54 95 100 94 83
1250.63 41.97 98 70 100 89 1489.49 42.21 95 90 94 72
3295.77 38.36 98 50 50 33 2442.06 46.85 95 70 81 67
3405.68 37.84 98 40 62 17 2279.06 47.16 95 70 69 44
1578.01 52.53 98 70 75 50 4748.51 25.38 95 50 38 33
1134.58 37.11 98 90 94 94 1766.84 35.15 95 100 100 100
Abbreviations are: CE, capillary electrophoresis; FSGS, focal segmental glomerulosclerosis; MCD, minimal change disease; MGN, membranous glomerulonephritis.
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Table 4. Results of the Random Forest statistical analysis:
Discrimination between healthy individuals and renal patients
Healthy Renal
subjects patients Classification
Class (N = 57) (N = 44) error %
Classified as healthy 56 2 3.5
Classified as patients 1 42 2.3
identified by the two parameters mass and capillary elec-
trophoresis migration time.
The examination of urine obtained from healthy sub-
jects led to the establishment of peaks defined by actual
mass and capillary electrophoresis time of the polypep-
tide detected, so-called peak lists, and contour plots for
each individual. The individual peak lists were deposited
in a mass spectrometry access database and the probabil-
ity of each of the polypeptides to appear in a single sam-
ple was calculated. One-hundred seventy-three polypep-
tides were present in over 90% of the control samples
examined. In addition, 156 polypeptides were present
in more than 75% of the samples, while additional 361
polypeptides were found in over 50% of samples from the
healthy individuals. These 690 polypeptides were found
in more than 50% of all samples obtained from healthy
subjects and were used to establish a “normal polypeptide
pattern.”
Urine from patients with renal diseases analyzed with
capillary electrophoresis-mass spectrometry
Data from the individual runs of 44 patients were
sub grouped in the three disease groups and analyzed.
The values from these databases, representing typical
polypeptide patterns, were subsequently compared. Sig-
nificant homology of the protein patterns present in urine
samples from each patient group was found within the
groups. Typical examples of urinary polypeptide patterns
from patients with MCD, FSGS, and MGN are shown
in Figure 2. Each disease presents a typical protein con-
tour plot, revealing more than 500 polypeptides. Subse-
quently, the data from the three groups were compared
with those obtained in healthy subjects. Table 3 shows
124 polypeptides found in the urine of more than 95%
of healthy subjects and reveals the differences to patients
with MCD, FSGS, and MGN.
Statistical analysis for discrimination of healthy indi-
viduals and patients with renal disease using capillary
electrophoresis-mass spectrometry data was applied. A
list of 800 polypeptides, present with more than 50%
probability in either disease group was chosen for Ran-
dom Forest analysis. As presented in Table 4, the cor-
rect classification rate for the discrimination between
healthy subjects and renal patients was 96.5%. After
cross-validation a sensitivity of 81.3% and a specificity
of 94.3% could be obtained. Discrimination of the dis-
ease groups was achieved in the learning sample. How-
ever, most likely due to the small number of FSGS
patients, these could not be discriminated from MCD
when applying cross-validation. Hence, FSGS and MCD
were combined into one group. For the discrimination
between healthy subjects, MCD/FSGS and MGN, four
polypeptides were selected by CART from the list to build
a classification tree with five terminal nodes (Table 5).
The correct classification rate in the learning sample is
94.1%. After cross-validation it reduces to 84.3% (93.8%
for healthy controls, 71.4% for MCD/FSGS and 92.9%
for MGN).
Alternatively, statistical analysis was performed using
support vector machines on the same data. Table 6 shows
polypeptides that were employed in this analysis. Using
these polypeptides, the correct classification was 98.0%
after complete cross-validation. Table 7 depicts polypep-
tides that were used to discriminate between MCD and
MGN. Here the correct classification was 94.1% after
complete cross-validation. Further, we could separate pa-
tients with MCD and FSGS and patients with MGN and
FSGS with (cross-validated) classification rates of 92.3%
and 89.3%, respectively (Table 7). These results can be
valued as a first approach using support vector machines
to classify a limited number of patients. With increas-
ing patient data, the classification will further improve
and become more stable. Our results also indicate that
for stable classification the number of applicable vari-
ables (polypeptides) depends on the number of cases (pa-
tients), hence an increase in patients will allow to use even
more polypeptides for classification.
DISCUSSION
Proteomics may add significantly to clinical diagnosis,
since co- and posttranslational protein modifications are
visualized, a feature missing in genomic approaches. This
report demonstrates that the online combination of capil-
lary electrophoresis and mass spectrometry is a feasible,
fast, sensitive and reproducible approach for the iden-
tification of urinary proteins. This first screening of pa-
tients with primary renal disease enabled the validation
of both the capillary electrophoresis-mass spectrometry
approach toward the creation of protein patterns and the
handling of the specifically developed software.
Examination of various techniques prior to the es-
tablishment of capillary electrophoresis-mass spectrom-
etry yielded unsatisfactory results with respect to reso-
lution and speed of the methods. Fractionation of the
sample with a stable, high-resolution method appeared
essential. Since capillary electrophoresis surpasses high-
performance liquid chromatography (HPLC) with re-
spect to resolution and speed and does not require tryptic
digestion, the direct coupling of capillary electrophore-
sis to a high-resolution time-of-flight mass spectrometry
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Table 5. Results of the Random Forest statistical analysis: Discrimination between patients with focal segmental glomerulosclerosis (FSGS),
membranous glomerulonephritis (MGN), and minimalchange disease (MCD)
Variable Capillary Frequency Frequency Frequency Frequency
number Mass D electroporesis time healthy % FSGS % MCD % MGN %
V309 1435.69 32.7 94 86 100 7
V23 1282.39 29.3 69 29 29 0
V216 3531.01 26.9 69 0 0 0
V251 5801.94 13.3 69 0 7 7
Table 6. Polypeptides used for support vector machines:
Discrimination between healthy individuals and renal patients
Capillary
Mass electrophoresis time
909.4 40.3
1159.6 39
1338.7 47.2
1686.8 38.2
1847.8 57
1966.3 25.1
1990.8 47.3
2146.3 25.8
2432.2 38.3
2465 22.8
3707 31.9
seemed most appropriate [15].This was further spurred
by Jensen et al [16], who reported the analysis of up
to 1000 native bacterial proteins in one single capillary
electrophoresis-mass spectrometry run. Alternative ap-
proaches are the classical method of comparing data from
two-dimensional electrophoresis, subsequent isolation of
the proteins from the gel, digestion and analysis via mass
spectrometry or mass spectrometry/mass spectrometry,
as presented by Thongboonkerd et al for urine samples
[17]. This method is too time-consuming for routine use,
however. In addition, smaller proteins are difficult or
even impossible to visualize using this technique. An-
other approach utilizing SELDI was recently presented
by several groups [8, 9]. The technology is well suited
for high throughput, but a major drawback might be the
loss of most proteins and peptides present in the sample
due to the matrices selecting for particular polypeptides.
This leads to the establishment of lower resolution pat-
terns that represent only a minority of proteins and pep-
tides present in a sample.
An elegant approach to identify urinary polypeptides
was published by Spahr et al [18]. The authors used HPLC
coupled to mass spectrometry/mass spectrometry. They
identified more than 100 polypeptides in urine. While
their approach results in the rapid identification of uri-
nary proteins, this method appears not well suited to ob-
tain a representative pattern of the polypeptides present
in a sample. The authors used tryptic digests of pooled hu-
man urinary proteins allowing identification of proteins
present, hence they were unable to obtain protein pat-
Table 7. Polypeptides used for support vector machines:
Discrimination between patients with membranous
glomerulonephritis (MGN), minimal change disease (MCD), and
focal segmental glomerulosclerosis (FSGS)
MGN vs. MCD
Mass Capillary electroporesis time
879.6 26.9
1279.7 38.3
1341.8 33.1
1404.9 29.4
1569.8 48.3
1574.8 33.9
1605.9 23.7
2527.3 40.8
5112.9 33.1
MCD vs. FSGS
Capillary
Mass electrophoresis time
1199.6 31
1826.9 50.8
2077.3 35.8
2258.9 33.6
2918 42.2
MGN vs. FSGS
Capillary
Mass electrophoresis time
2312.5 22.9
2453.6 32
2639.6 45.2
9182 17.1
terns of individual samples or perform comparisons for
diagnostic purposes.
In contrast, capillary electrophoresis-mass spectrome-
try represents a tool to visualize a large number of native
polypeptides, resulting in proteomic patterns allowing
comparison of healthy subjects and different subsets of
patients. The technique may be applied to other body
fluids as well. A large number of polypeptides can be
found in single individual samples. This result was to be
expected and reflects both inter-individual differences as
well as changes in the spectrum of urinary proteins due
to diet, exercise, etc. More thorough examination of a
larger group of samples/individuals will eventually lead
toward the identification of polypeptides only present
under certain conditions (e.g., after exercise). The mass
tables provided by MosaiquesVisu allowed application
of statistical analysis to all masses generated for each
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individual. These individual data were compared within
the healthy volunteers and allowed the establishment of
a normal protein pattern. As evident from Table 3, sev-
eral polypeptides significant for healthy individuals or a
particular disease group could be defined. These proteins,
serving as possible markers for MCD, FSGS, and MGN,
will be further identified using mass spectrometry/mass
spectrometry analysis.
CONCLUSION
Our data indicate that this technology can be used to es-
tablish a normal proteomic pattern in urine. Moreover, it
is a promising approach toward diagnosing patients with
renal diseases as an alternative to more invasive and/or
time consuming diagnostic procedures.
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